Source-grounded facts extracted from Enveric Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Enveric Biosciences, Inc. shareholders approved Ratification of appointment of CBIZ CPAs P.C. as independent auditor at the 2026-05-28 meeting.
“5. The votes cast on the Auditor Ratification Proposal were as follows: Votes Against Abstentions 960,728 19,347 11,753”
Enveric Biosciences, Inc. shareholders rejected Authorized Stock Increase Proposal at the 2026-05-28 meeting.
“4. The votes cast on the Authorized Stock Increase Proposal were as follows: Votes Against Abstentions 427,158 555,147 9,523”
Enveric Biosciences, Inc. shareholders approved Reverse Stock Split Proposal at the 2026-05-28 meeting.
“3. The votes cast on the Reverse Stock Split Proposal were as follows: Votes Against Abstentions 793,344 190,175 8,309”
Enveric Biosciences, Inc. shareholders approved Say-on-Pay Proposal at the 2026-05-28 meeting.
“2. The votes cast on the advisory vote for the Say-on-Pay Proposal were as follows: Votes Against Abstentions Broker Non-Votes 569,552 26,884 5,297 390,095”
Enveric Biosciences, Inc. shareholders approved Election of Directors at the 2026-05-28 meeting.
“1. The votes cast on the Election of Directors were as follows: Nominee Votes For Withheld Broker Non-Votes Michael Webb 564,143 37,590 390,095 George Kegler 531,522 70,211 390,095 Frank Pasqualone 531,937 69,796 390,095 Marcus Schabacker, M.D., Ph.D. 566,038 35,695 390,095 Joseph Tucker, Ph.D. 565,386 36,347 390,095 Sheila DeWitt, Ph.D 565,534 36,199 390,095”
Enveric Biosciences, Inc. reported the quarter ended March 31, 2025 results: net income net loss of $2.2 million, EPS basic and diluted loss per share of $14.58.
“as compared to a net loss of $2.2 million, including $0.3 million in net non-cash income, with a basic and diluted loss per share of $14.58 for the quarter ended March 31, 2025”
Enveric Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss attributable to stockholders was $1.6 million, EPS basic and diluted loss per share of $1.08.
“Net loss attributable to stockholders was $1.6 million for the first quarter ended March 31, 2026, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $1.08”
Enveric Biosciences, Inc. issued Placement Agent Warrants to purchase up to 7.0% of the aggregate number of shares of Common Stock placed in the Private Placement, equating to 155,556 shares of of warrant to designees of the Placement Agent for exercise price equal to $2.8125 per share.
“Shares”). The Placement Agent Warrants have substantially the same terms as the Series I Warrants, except that the Placement Agent Warrants have an exercise price equal to $2.8125 per share. The Company agreed to indemnify the Placement Agent against certain liabilities relating to or arising out of the Placement Agent’s activities under the Engagement”
Enveric Biosciences, Inc. issued Series J warrants to purchase up to 2,222,223 shares of Common Stock of warrant to institutional investors for exercise price of $2.00 per share.
“shares issuable upon exercise thereof, the “Series J Warrant Shares,” together with the Series I Warrant Shares, the “Warrant Shares”). The Warrants have an exercise price of $2.00 per share (subject to customary adjustments as set forth in the Warrants) and are exercisable immediately. The Series I Warrants will expire five (5) years following the effective”
Enveric Biosciences, Inc. issued Series I warrants to purchase up to 2,222,223 shares of Common Stock of warrant to institutional investors for exercise price of $2.00 per share.
“shares issuable upon exercise thereof, the “Series J Warrant Shares,” together with the Series I Warrant Shares, the “Warrant Shares”). The Warrants have an exercise price of $2.00 per share (subject to customary adjustments as set forth in the Warrants) and are exercisable immediately. The Series I Warrants will expire five (5) years following the effective”
Enveric Biosciences, Inc. issued Pre-Funded Warrants to purchase up to an aggregate of 2,124,223 shares of Common Stock of warrant to institutional investors for nominal exercise price of $0.0001 per share.
“that in no event shall the Beneficial Ownership Limitation exceed 9.99%. The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full. A holder may not exercise any portion of the Pre-Funded Warrants to the extent”
Enveric Biosciences, Inc. issued 98,000 shares of common stock to institutional investors for approximately $5.0 million.
“and Exchange Commission). The Private Placement closed on April 17, 2026. The gross proceeds to the Company from the Private Placement are expected to be approximately $5.0 million, before deducting placement agent fees and expenses and estimated offering expenses payable by the Company, with the potential for up to approximately $8.9 million of additional”
Enveric Biosciences, Inc. entered into Registration Rights Agreement with each Investor valued at Company agreed to file resale registration statement within 15 days and use best efforts to have it (effective 2026-04-16).
“In connection with the Private Placement, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of April 16, 2026, with each Investor, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of Shares, Pre-Funded Warrant Shares, and Warrant Shares, no later than 15 days after the date of the Registration Rights Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days following the date of the Registration Rights Agreement (or 75 days following the date of the Registration Rights Agreement in the event of a “full review” by the Securities and Exchange Commission).”
Enveric Biosciences, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC with H.C. Wainwright & Co., LLC valued at Cash fee of 7.0% of aggregate gross proceeds plus management fee of 1.0% and expense reimbursement; (effective 2024-12-08).
“H.C. Wainwright & Co., LLC (the “Placement Agent”) acted as the exclusive placement agent in connection with the Private Placement under an Engagement Letter, dated as of December 8, 2024, as amended on January 14, 2025, June 5, 2025, November 10, 2025, and December 16, 2025 (the “Engagement Letter”).”
Enveric Biosciences, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $5.0 million gross proceeds expected, with potential for up to $8.9 million additional upon exercise (effective 2026-04-16).
“On April 16, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors” and each, an “Investor”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) 98,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,124,223 shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) Series I warrants to purchase up to 2,222,223 shares of Common Stock (the “Series I Warrants,” and the shares issuable upon exercise thereof, the “Series I Warrant Shares”), and (iv) Series J warrants to purchase up to 2,222,223 shares of Common Stock (the “Series J Warrants,” together with the Series I Warrants, the “Warrants” and the shares issuable upon exercise ther”
Enveric Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Enveric Biosciences, Inc. issued up to 23,016 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (Placement Agent) for exercise price equal to $5.5125 per share.
“Agent Warrants”) to purchase up to 23,016 shares of Common Stock to the Placement Agent (including its designees). The Placement Agent Warrants have an exercise price equal to $5.5125 per share and are exercisable for five (5) years from the commencement of sales in the Offerings. The Common Warrants and Placement Agent Warrants and the shares of our Common”
Enveric Biosciences, Inc. issued up to 328,802 shares of Common Stock of warrant to certain institutional investors for exercise price of $4.16 per share.
“up to 328,802 shares of Common Stock (the “Series H Warrants”, and collectively with the Series G Warrants, the “Common Warrants”). The Common Warrants have an exercise price of $4.16 per share (subject to customary adjustments as set forth in the Common Warrants) and are exercisable immediately. The Series G Warrants will expire five (5) following the”
Enveric Biosciences, Inc. issued 328,802 shares of common stock to certain institutional investors for $4.41 per share.
“the Company agreed to issue and sell to the Investors in a registered direct offering, an aggregate of 328,802 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price of $4.41 per share”
Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2026-01-27).
“On January 27, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (each, an “Investor”)”
Enveric Biosciences, Inc. entered into Inducement Letters with certain institutional investors valued at aggregate gross proceeds of approximately $3.1 million (effective 2025-12-11).
“On December 11, 2025, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain institutional investors (the “Holders”) that held certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively (collectively, the “Existing Warrants”).”
Enveric Biosciences, Inc. issued up to 426,390 shares of warrant to certain institutional investors for $7.05 per share exercise price and $0.125 per share purchase price.
“(collectively, the “Existing Warrants”). Pursuant to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $7.05 per share and pay a purchase price of $0.125 per share in consideration for the Company’s agreement to issue in a private placement (x) new Series E Common Stock Purchase Warrants”
Enveric Biosciences, Inc.: Certificate of Amendment filed to effect 1-for-12 reverse stock split of common stock (effective 2025-10-28).
“On October 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-12 reverse stock split of the shares of the Company’s Common Stock, either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on October 28, 2025 (the “Reverse Stock Split”).”
Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“the “Company”) received a notice from The Nasdaq Stock Market (the “Nasdaq”) indicating that it no longer met the continued listing requirements. Specifically, the Company’s stockholders’ equity was below the minimum required stockholders’ equity of $2.5 million as stipulated by Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). As noted in the Original 8-K, the Company had until October 10, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on October 10, 2025. The Company is filing this Current Report on Form 8-”
Enveric Biosciences, Inc. issued up to 2,424,998 shares of Common Stock of warrant to certain institutional investors (the "Holders") for aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees.
“(the “New Series D Warrant Shares” and, together with the New Series C Warrant Shares, the “New Warrant Shares.”) The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other offering expenses payable by the Company. The Company engaged H.C.”
Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 26, 2025, Enveric Biosciences, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, r”
Enveric Biosciences, Inc. engaged CBIZ CPAs P.C. as its auditor.
“CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately”
Enveric Biosciences, Inc. dismissed Marcum LLP as its auditor.
“On April 14, 2025, the Company dismissed Marcum as the Company’s independent registered public accounting firm”
Enveric Biosciences, Inc.: Filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of common stock (effective 2025-01-27).
“On January 17, 2025, Enveric Biosciences, Inc. (the “Company”) filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on January 27, 2025 (the “Reverse Stock Split”).”
Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 16, 2024, Enveric Biosciences, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notificat”
Enveric Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income $2.46 million, EPS $0.61.
“Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.”
Enveric Biosciences, Inc. entered into Purchase Agreements with certain institutional investors valued at at a deemed offering price of $0.94 per share (effective 2024-05-03).
“On May 3, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreements”) for the issuance in a registered direct offering of an aggregate of 458,000 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.”
Enveric Biosciences, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: net income $3.44 million for the fourth quarter ended December 31, 2023, EPS $1.46.
“Net loss attributable to stockholders was $3.44 million for the fourth quarter ended December 31, 2023, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46, as compared to a net loss of $8.80 million, including $4.48 million in net non-cash expense, with a basic and diluted loss per share of $4.89 for the quarter ended December 31, 2022.”
Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-03-08).
“On March 8, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreement”) for the issuance in a registered direct offering of 228,690 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.”
Enveric Biosciences, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
“February 6, 2024, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Enveric Biosciences, Inc. (the “Company”) that based on the Staff’s review of materials submitted by the Company to Nasdaq, the Staff determined to grant the Company an extension to regain compliance with the minimum stockholders’ equity requirement of at least $2,500,000 as set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”). The deficiency with respect to the Company’s compliance with the S”
Enveric Biosciences, Inc. announced a restructuring with charges of approximately $40,000 (approximately seven positions, representing approximately 50% of the Company's global workforce).
“to decrease its costs and create a more streamlined organization to support its business. In connection with the RIF, the Company currently estimates it will incur approximately $40,000 of costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the first quarter of 2024.”
Enveric Biosciences, Inc. entered into Inducement Letters with certain holders valued at approximately $1.8 million (effective 2023-12-28).
“On December 28, 2023, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock (the “Existing Warrants”) pursuant to which the Holders agreed to exercise for cash their Existing Warrants to purchase 1,122,000 shares of the Company’s common stock, in the aggregate, at a reduced exercised price of $1.37 per share, in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”)”
Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, reported stockholders’ equity of $2,435,646. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of”
Enveric Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 13, 2023, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.”
Enveric Biosciences, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $10.0 million (effective 2023-11-03).
“On November 3, 2023, Enveric Biosciences, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock”
Enveric Biosciences, Inc. shareholders approved Approval of the issuance of shares of common stock to Lincoln Park Capital Fund, LLC pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d). at the 2023-11-02 meeting.
“Approval of the issuance of shares of common stock to Lincoln Park Capital Fund, LLC pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d).”
Enveric Biosciences, Inc. shareholders approved Approval of proposed amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. at the 2023-11-02 meeting.
“Approval of proposed amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended.”
Enveric Biosciences, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-11-02 meeting.
“Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Enveric Biosciences, Inc. shareholders approved Non-binding advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2023-11-02 meeting.
“Non-binding advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Enveric Biosciences, Inc. shareholders approved Election of five directors, to serve until the Company's 2024 annual meeting of stockholders or until their successors are duly elected and qualified. at the 2023-11-02 meeting.
“On November 2, 2023, the Company held its 2023 Annual Meeting.”
Enveric Biosciences, Inc. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at up to $10.0 million (effective 2023-09-01).
“On September 1, 2023, Enveric Biosciences, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”), with Canaccord Genuity LLC (“Canaccord”), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $10.0 million.”
Enveric Biosciences, Inc. reported second quarter of 2023 ended June 30, 2023 results: net income $6.40 million, EPS $3.04.
“Net loss attributable to shareholders was $6.40 million for the second quarter ended June 30, 2023, including $1.64 million in net non-cash expenses, with a basic and diluted loss per share of $3.04, as compared to a net loss of $2.87 million and non-cash income of $1.04 million, with primary and diluted loss per share of $2.73 per share for the quarter ended June 30, 2022.”
Avani Kanubaddi was terminated as President and Chief Operating Officer at Enveric Biosciences, Inc..
“the Company terminated the employment contract of Mr. Kanubaddi without Cause (as defined in the Employment Agreement), the President and Chief Operating Officer of the Company, to be effective June 17, 2023”
Enveric Biosciences, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.3 million, EPS $13.00.
“Comprehensive net loss was $19.3 million for the year ended December 31, 2022, including $2.4 million in net non-cash expenses, with a basic and diluted loss per share of $13.00”
Robert Dickey IV departed as chief financial officer at Enveric Biosciences, Inc..
“Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.